Centivax Drives Next-Generation COVID-19 Antibody into the Clinic
Excerpt from the Press Release:
When COVID-19 shut down the world’s economies, governments across the globe, including the United States, began to pour money into vaccine research and development. Those funds led to the rapid development and deployment of vaccines, but few therapeutics against the virus have achieved the same speed of development. And that may be a problem as the virus shifts from pandemic to endemic.
“The virus will not be eradicated through vaccination alone. That means… we need our medicines. That was a failure of 2020 that doesn’t get enough emphasis,” Jake Glanville, chief executive officer of Bay Area-based Centivax, told BioSpace in an interview.
Glanville praised the swift response from the industry to develop vaccines that are highly effective against the original strain of the virus, as well as limited efficacy against emerging strains. However, he said more medications are needed, particularly as it appears herd immunity may not be achieved any time soon.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?